Why doesn't anyone take the company's word at face
Post# of 72440
They have proof of concept now with Kevetrin in the IV formulation.
IV formulations are expensive to administer, inconvenient for the patient, and make it difficult for multiple doses per day.
Therefore, the company is trying to develop an oral formulation which will be cheaper and easier for the patient, and which will allow multiple doses per day.
Why does this not make sense to people? Why is it viewed as a negative, when in fact it is a very smart move?